Omniox is an early stage biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia (oxygen deficiency) impacts cancer, cardiovascular diseases, trauma and many other conditions. At Omniox, we have engineered an unusually stable oxygen carrier technology (H-NOX) to deliver oxygen into hypoxic tissues and improve the treatment of severe unmet medical needs. We believe our approach overcomes the modes of failure of prior efforts in the field of oxygen therapeutics. By specifically oxygenating pathologically hypoxic tissues, OMX biologics restore normal tissue function with the potential for improved outcomes and patient cures.